{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:57:41Z","timestamp":1794967061365,"version":"4.9.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator, elexacaftor\u2013tezacaftor\u2013ivacaftor, is now widely being used by people with cystic fibrosis. However, few independent studies have detailed the pharmacokinetics (PK) of CFTR modulators. Blood collection by venipuncture is the gold standard for PK measurements, but it is invasive. The aim of this study was to develop and clinically validate a quantification method for elexacaftor, tezacaftor, ivacaftor, and their main metabolites in dried blood spots (DBSs) using liquid chromatography with tandem mass spectrometry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Linearity, accuracy, precision, stability, hematocrit (Hct), spot-to-spot carryover, spot volume, and extraction efficiency were validated in DBS for all analytes. The clinical validation of elexacaftor\u2013tezacaftor\u2013ivacaftor in patients was performed by comparing 21 DBS samples with matched plasma samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The preset requirements for linearity, within-run and between-run accuracy, precision, Hct, spot volume, and extraction efficiency were met. Puncher carryover was observed and resolved by punching 3 blanks after each sample. The samples remained stable and showed no notable degradation across the tested temperatures and time intervals. Corrected DBS values with the Passing\u2013Bablok regression equation showed good agreement in Bland\u2013Altman plots, and acceptance values were within 20% of the mean for a minimum of 67% of the repeats, according to the EMA guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A quantification method for the analysis of elexacaftor, tezacaftor, ivacaftor, and their main metabolites was developed and clinically validated in DBS. This method could be valuable in both clinical care and research to address unanswered PK questions regarding CFTR modulators.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001231","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T21:00:24Z","timestamp":1719349224000},"page":"804-812","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS\/MS"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9905-7805","authenticated-orcid":false,"given":"Steffie E. M.","family":"Vonk","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"van der Meer-Vos","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Kos","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne H.","family":"Neerincx","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne W. J.","family":"Terheggen-Lagro","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pulmonology and Allergy, Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Amsterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josje","family":"Altenburg","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke H.","family":"Maitland-van der Zee","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A. A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Marleen","family":"Kemper","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;"},{"name":"Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Amsterdam Mucociliary Clearance Disease (AMCD) research group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/cpt.548","article-title":"Can cystic fibrosis patients finally catch a breath with lumacaftor\/ivacaftor?","volume":"101","author":"Schneider","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic Review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor: multidimensional assessment of neuropsychological side effects and physical and mental health outcomes in adolescents and adults","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R16-20250603","first-page":"100270","article-title":"Telemedicine in cystic fibrosis","volume":"26","author":"Desimone","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/FTD.0000000000000994","article-title":"Best practices to implement dried blood spot sampling for therapeutic drug monitoring in clinical practice","volume":"44","author":"Francke","year":"2022","journal-title":"Ther Drug Monit"},{"issue":"4","key":"R18-20250603","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FTD.0000000000000829","article-title":"A quantitative method for the analysis of ivacaftor, hydroxymethyl ivacaftor, ivacaftor carboxylate, lumacaftor, and tezacaftor in plasma and sputum using LC-MS\/MS and its clinical applicability","volume":"43","author":"Vonk","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"e01015","DOI":"10.1002\/prp2.1015","article-title":"Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1515\/cclm-2019-0053","article-title":"Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients","volume":"57","author":"Veenhof","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1111\/bcp.13755","article-title":"Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device","volume":"84","author":"Zwart","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1515\/cclm-2021-0724","article-title":"Isotope dilution LC-MS\/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum","volume":"60","author":"Habler","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/biomedicines11020628","article-title":"Simultaneous quantification of ivacaftor, tezacaftor, and elexacaftor in cystic fibrosis patients' plasma by a novel LC-MS\/MS method","volume":"11","author":"Pigliasco","year":"2023","journal-title":"Biomedicines"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor, and elexacaftor treatment response in cystic fibrosis: a high-throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcf.2006.05.012","article-title":"Laboratory parameter profiles among patients with cystic fibrosis","volume":"6","author":"Goss","year":"2007","journal-title":"J Cyst Fibros"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:17:23Z","timestamp":1748971043000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001231","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"2024-01-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}